Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Patou

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Scandinavian Journal of Infectious Diseases|January 1, 1991
Prevalence of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor poolsH Rollag, G Patou, J R Pattison, et al.
Lancet (London, England)|May 15, 1993
Human parvovirus infection in homozygous sickle cell diseaseG R Serjeant, B E Serjeant, P W Thomas, et al.
The Journal of Infection|February 12, 1998
A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjectsB S Peters, R Cheingsong-Popov, D Callow, et al.
Lancet (London, England)|May 23, 1987
Treatment of first-attack genital herpes--acyclovir versus inosine pranobexA Mindel, G Kinghorn, E Allason-Jones, et al.
Vaccine|June 1, 1995
Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteersJ Weber, R Cheinsong-Popov, D Callow, et al.
The American Review of Respiratory Disease|June 1, 1990
Cytomegalovirus in the lungs of patients with AIDS. Respiratory pathogen or passenger?A B Millar, G Patou, R F Miller, et al.
AIDS Research and Human Retroviruses|March 20, 1997
Gag-specific immune responses after immunization with p17/p24:Ty virus-like particles in HIV type 1-seropositive individualsM R Klein, J Veenstra, A M Holwerda, et al.
HIV Medicine|December 12, 2001
Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell declineD Smith, I Gow, R Colebunders, et al.
AIDS (London, England)|February 19, 1998
Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network InvestigatorsA D Kelleher, M Roggensack, A B Jaramillo, et al.
AIDS Research and Human Retroviruses|February 24, 1999
Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individualsE M Benson, J Clarkson, M Law, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Scandinavian Journal of Infectious Diseases|January 1, 1991
Prevalence of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor poolsH Rollag, G Patou, J R Pattison, et al.
Lancet (London, England)|May 15, 1993
Human parvovirus infection in homozygous sickle cell diseaseG R Serjeant, B E Serjeant, P W Thomas, et al.
The Journal of Infection|February 12, 1998
A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjectsB S Peters, R Cheingsong-Popov, D Callow, et al.
Lancet (London, England)|May 23, 1987
Treatment of first-attack genital herpes--acyclovir versus inosine pranobexA Mindel, G Kinghorn, E Allason-Jones, et al.
Vaccine|June 1, 1995
Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteersJ Weber, R Cheinsong-Popov, D Callow, et al.
The American Review of Respiratory Disease|June 1, 1990
Cytomegalovirus in the lungs of patients with AIDS. Respiratory pathogen or passenger?A B Millar, G Patou, R F Miller, et al.
AIDS Research and Human Retroviruses|March 20, 1997
Gag-specific immune responses after immunization with p17/p24:Ty virus-like particles in HIV type 1-seropositive individualsM R Klein, J Veenstra, A M Holwerda, et al.
HIV Medicine|December 12, 2001
Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell declineD Smith, I Gow, R Colebunders, et al.
AIDS (London, England)|February 19, 1998
Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network InvestigatorsA D Kelleher, M Roggensack, A B Jaramillo, et al.
AIDS Research and Human Retroviruses|February 24, 1999
Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individualsE M Benson, J Clarkson, M Law, et al.
Pageof 4